Product Images Escitalopram Oxalate

This text provides information about a medication with NDC 43602-474, containing 10 mg of escitalopram equivalent to 12.75 mg of escitalopram oxalate in each tablet. It includes instructions to keep the drug in a tight container, store it at room temperature, and has details for pharmacists to dispense the tablets. It also mentions a medication guide for patients and provides manufacturing details from Ascend Pharmaceuticals, Inc.*

This text provides information about a medication called Escitalopram in tablet form. It contains 10 mg of escitalopram, equivalent to 12.75 mg of escitalopram oxalate per tablet. The recommended usual dosage should be checked in the package insert. The pharmacist is instructed to dispense a Medication Guide to each patient. It should be kept out of reach of children and stored at 20° to 25°C (68° to 77°F), with excursions permitted between 15° to 30°C (59° to 86°F). The medication is manufactured by Ascent Pharmaceuticals, Inc. in Central Islip, NY 11722.*

This text indicates information about a medication with NDC 43602-475-10, each tablet containing 20 mg of escitalopram. The usual dosage and storage instructions are provided, along with the manufacturer details, Ascent Pharmaceuticals, Inc. in Central Islip, NY 11722. It is important to follow the medication guide, keep the drugs out of reach of children, and store them properly.*

This is a pharmaceutical label for Escitalopram Tablets, containing 20 mg of escitalopram. It provides information on how to dispense the medication, dosage instructions, storage guidelines, and manufacturer details. It is important for pharmacists to dispense the accompanying Medication Guide to each patient. The tablets should be kept in a tight container, stored at 20° to 25°C (68° to 77°F), with excursions permitted between 15 to 30°C (59° to 86°F). The manufacturer is Ascent Pharmaceuticals, Inc. located in Central Islip, NY 11722.*

This is a description of a medication called Escitalopram Tablets, USP, containing 5 mg of escitalopram, equivalent to 6.38 mg of escitalopram oxalate per tablet. The usual dosage information can be found in the package insert. Pharmacists are reminded to dispense the accompanying Medication Guide to each patient. It is advised to keep all drugs out of reach of children and store in a tight container at 20° to 25°C (68° to 77°F). Excursions between 15° to 30°C (59° to 86°F) are permitted. The medication is manufactured by Ascent Pharmaceuticals, Inc. in Central Islip, NY 11722.*

This is a description of a medication called Escitalopram Tablets, USP, with each tablet containing 5 mg of escitalopram. The usual dosage information is available in the package insert. The pharmacist is advised to dispense the accompanying Medication Guide to each patient. The medication should be stored at 20° to 25°C (68° to 77°F) with excursions permitted between 15° to 30°C (59° to 86°F). The manufacturer is Ascent Pharmaceuticals, Inc. located in Central Islip, NY.*

This text provides information about various drug interactions involving Escitalopram, Pimozide, other Serotonergic Drugs, Drugs that interfere with Hemostasis, Sumatriptan, and Carbamazepine. Specifically, the text warns about the potential risks and clinical impacts of combining these drugs with Escitalopram, such as serotonin syndrome, QT prolongation, bleeding complications, and changes in pharmacokinetics. It also outlines interventions to manage these interactions, including discontinuation of certain drugs, monitoring for symptoms, and considering dosage adjustments. Monitoring and individualized patient care are highlighted as essential components when dealing with these drug interactions.*

This text describes the potential interaction between escitalopram and desipramine, a tricyclic antidepressant metabolized by CYP2D6. Coadministration of escitalopram with desipramine resulted in a significant increase in desipramine levels in the body. The clinical significance of this finding is unknown, so caution is advised when coadministering escitalopram with drugs metabolized by CYP2D6.*

This text provides a summary of adverse reactions observed with Escitalopram compared to a placebo for Major Depressive Disorder in adults. The table includes percentages for various adverse reactions, such as dry mouth, nausea, diarrhea, dizziness, and others. It also notes specific reactions related to different bodily systems including autonomic nervous system disorders, central and peripheral nervous system disorders, gastrointestinal disorders, psychiatric disorders, respiratory system disorders, and urogenital issues. The data is segmented by gender for certain reactions related to sexual health.*

This excerpt presents a table showing the incidence of common adverse reactions in patients with Major Depressive Disorder for Placebo, 10 mg/day Escitalopram, and 20 mg/day Escitalopram. Adverse reactions include Insomnia, Diarrhea, Dry Mouth, Somnolence, Dizziness, sweating, Increased Constipation, Fatigue, and Indigestion. It gives percentages for each adverse reaction for the respective treatment groups.*

This table shows the incidence of sexual side effects in placebo-controlled clinical trials for escitalopram. In males, common side effects included ejaculation disorder (primarily ejaculatory delay), decreased libido, and impotence. The percentage of males experiencing these side effects ranged from 2% to 6%. In females, decreased libido and anorgasmia were reported with a prevalence of 3%. The data provides insights into the sexual side effects associated with escitalopram use.*

This data table presents the risk differences in the number of patients experiencing suicidal thoughts and behaviors when treated with antidepressants in pediatric and adult patients. The table shows that in patients under 18 years old, there were 14 additional patients with suicidal thoughts and behaviors per 1000 patients treated compared to a placebo. In the 18 to 24 age group, there were 5 additional patients. However, in the 25 to 64 age group, there was 1 fewer patient, and in patients older than 65 years old, there were 6 fewer patients compared to placebo.*

This table shows adverse reactions observed with a frequency of equal to or greater than 2% compared to a placebo for Generalized Anxiety Disorder in adults. Adverse reactions for escitalopram, the active ingredient, are compared to a placebo. Common adverse reactions include dry mouth, increased sweating, headache, nausea, diarrhea, insomnia, fatigue, and changes in libido. It also includes specific details on the frequencies of various adverse reactions across different body systems such as the autonomic nervous system, gastrointestinal system, and psychiatric disorders.*